Mirum Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MIRM and other ETFs, options, and stocks.

About MIRM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. 

CEO
Christopher Peetz
CEOChristopher Peetz
Employees
372
Employees372
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
2018
Founded2018
Employees
372
Employees372

MIRM Key Statistics

Market cap
5.55B
Market cap5.55B
Price-Earnings ratio
-6.02
Price-Earnings ratio-6.02
Dividend yield
—
Dividend yield—
Average volume
927.71K
Average volume927.71K
High today
$89.00
High today$89.00
Low today
$85.36
Low today$85.36
Open price
$88.85
Open price$88.85
Volume
901.37K
Volume901.37K
52 Week high
$130.00
52 Week high$130.00
52 Week low
$63.23
52 Week low$63.23

Stock Snapshot

Mirum Pharmaceuticals(MIRM) stock is priced at $87.15, giving the company a market capitalization of 5.55B. It carries a P/E multiple of -6.02.

As of 2026-09-30, Mirum Pharmaceuticals(MIRM) stock has fluctuated between $85.36 and $89.00. The current price stands at $87.15, placing the stock +2.1% above today's low and -2.1% off the high.

Mirum Pharmaceuticals(MIRM) shares are trading with a volume of 901.37K, against a daily average of 927.71K.

During the past year, Mirum Pharmaceuticals(MIRM) stock moved between $63.23 at its lowest and $130.00 at its peak.

During the past year, Mirum Pharmaceuticals(MIRM) stock moved between $63.23 at its lowest and $130.00 at its peak.

MIRM News

Reuters 2d
Mirum's liver infection drug lowers virus levels in late-stage study - Reuters

...

Mirum's liver infection drug lowers virus levels in late-stage study - Reuters
TipRanks 2d
Mirum’s Brellovitug Phase 3 Success Signals Transformational Growth

Mirum Pharmaceuticals ( (MIRM) ) has shared an announcement. On September 25, 2026, Mirum and Incyte announced U.S. FDA approval of Atebrioz tablets, a once‑da...

TipRanks 2d
Mirum Pharmaceuticals says primary endpoint met in Phase 3 AZURE-1 study

Mirum Pharmaceuticals (MIRM) announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an investigational fully...

Analyst ratings

100%

of 14 ratings
Buy
100%
Hold
0%
Sell
0%

More MIRM News

TipRanks 5d
Mirum Pharmaceuticals, Incyte announce FDA approval of Atebrioz

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced that the U.S. FDA has approved Atebrioz tablets to reduce the volume of total new heterotopic ossificat...

People also own

Based on the portfolios of people who own MIRM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.